Home > Insider Trading > Filing (0001415889-24-023290)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1671858	Ars Pharmaceuticals Inc.	SPRY	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1378550	E Richard Lowenthal	C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-09-10	50,000	$11.50	1,396,494	No	4	S	Indirect	By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
Common Stock	Disposition	2024-09-10	50,000	$11.50	1,448,499	No	4	S	Indirect	By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
No	4	S	Indirect	By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,315,313	Direct
Common Stock	1,497,447	Indirect	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
Common Stock	3,407,847	Indirect	By Spouse

Footnotes

The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
The weighted average sale price for the transaction reported was $11.4973, and the range of prices were between $11.28 and $11.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The Reporting Person is trustee of the trust.
The weighted average sale price for the transaction reported was $11.4982, and the range of prices were between $11.28 and $11.82. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
The Reporting Person's spouse is trustee of the Trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.